Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

May 01, 1996; Volume 277,Issue 2
  • You have access
    Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase.
    B McAdam, R M Keimowitz, M Maher and D J Fitzgerald
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 559-564;
  • You have access
    Protective effects of dilazep and its novel derivative, K-7259, on mechanical and metabolic derangements induced by hydrogen peroxide in the isolated perfused rat heart.
    A Hara and Y Abiko
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 565-571;
  • You have access
    The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats.
    T Kawata, S Hashimoto and T Koike
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 572-577;
  • You have access
    The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents.
    L J Bristow, K L Flatman, P H Hutson, J J Kulagowski, P D Leeson, L Young and M D Tricklebank
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 578-585;
  • You have access
    In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
    D R Compton, M D Aceto, J Lowe and B R Martin
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 586-594;
  • You have access
    Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine.
    L Y Lin, M Fujimoto, E W Distefano, D A Schmitz, A Jayasinghe and A K Cho
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 595-603;
  • You have access
    Identification of genetic markers for initial sensitivity and rapid tolerance to ethanol-induced ataxia using quantitative trait locus analysis in BXD recombinant inbred mice.
    E J Gallaher, G E Jones, J K Belknap and J C Crabbe
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 604-612;
  • You have access
    Evaluation of potential genetic associations between ethanol tolerance and sensitization in BXD/Ty recombinant inbred mice.
    T J Phillips, C N Lessov, R D Harland and S R Mitchell
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 613-623;
  • You have access
    Common genetic determinants of the ataxic and hypothermic effects of ethanol in BXD/Ty recombinant inbred mice: genetic correlations and quantitative trait loci.
    J C Crabbe, T J Phillips, E J Gallaher, L I Crawshaw and S R Mitchell
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 624-632;
  • You have access
    Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats.
    K Fecho, K A Maslonek, L A Dykstra and D T Lysle
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 633-645;
  • You have access
    Neurotoxin-induced lesions to central serotonergic, noradrenergic and dopaminergic systems modify caffeine-induced antinociception in the formalin test and locomotor stimulation in rats.
    J Sawynok and A Reid
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 646-653;
  • You have access
    Electrical stimulation at traditional acupuncture sites in periphery produces brain opioid-receptor-mediated antinociception in rats.
    X H Chen, E B Geller and M W Adler
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 654-660;
  • You have access
    4-(2'-Methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p-iodobenzamido]ethyl] piperazine and 4-(2'-methoxyphenyl)-1-[2'-[N-(2"-pyridinyl)-p- fluorobenzamido]ethyl]piperazine, two new antagonists at pre- and postsynaptic serotonin-1A receptors.
    R J Thielen, N B Fangon and A Frazer
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 661-670;
  • You have access
    Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction.
    J J Lynch, A A Wallace, G L Stump, R F Stupienski, T Kothstein and J R Gehret
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 671-678;
  • You have access
    Identification and characterization of a high-affinity leukotriene B4 receptor on guinea pig T lymphocytes and its regulation by lipoxin A4.
    K T Lin, A Dudhane, H P Godfrey and P Y Wong
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 679-684;
  • You have access
    1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
    T Coleman, S W Ellis, I J Martin, M S Lennard and G T Tucker
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 685-690;
  • You have access
    The effects of administering quinacrine during ultraprofound hypothermia on warm ischemic kidney cortex tissue.
    J F McAnulty and X Q Huang
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 691-699;
  • You have access
    Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate.
    S Palea, M Corsi, W Artibani, E Ostardo and C Pietra
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 700-705;
  • You have access
    Halothane constricts bovine pulmonary arteries by release of intracellular calcium.
    D M Fehr, D R Larach, K A Zangari and H G Schuler
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 706-713;
  • You have access
    The 21-aminosteroid tirilazad mesylate protects against liver injury via membrane stabilization not inhibition of lipid peroxidation.
    Y Wang, W R Mathews, D M Guido and H Jaeschke
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 714-720;
  • You have access
    Alterations in calcium antagonist receptors and calcium content in senescent brain and attenuation by nimodipine and nicardipine.
    S Yamada, S Uchida, T Ohkura, R Kimura, M Yamaguchi, M Suzuki and M Yamamoto
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 721-727;
  • You have access
    Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
    G M Bores, F P Huger, W Petko, A E Mutlib, F Camacho, D K Rush, D E Selk, V Wolf, R W Kosley, L Davis and H M Vargas
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 728-738;
  • You have access
    Discriminative effects of CGS 15943, a competitive adenosine receptor antagonist, in monkeys: comparison to methylxanthines.
    S G Holtzman
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 739-746;
  • You have access
    Non-neuronal release of ATP and inositol 1,4,5-trisphosphate accumulation evoked by P2- and M-receptor stimulation in guinea pig ileal segments.
    T Katsuragi, K Matsuo, C Sato, K Honda, H Kamiya and T Furukawa
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 747-752;
  • You have access
    Frequency modulation of acetylcholine-induced oscillations in Ca++ and Ca(++)-activated Cl- current by cAMP in tracheal smooth muscle.
    L C Nuttle and J M Farley
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 753-760;
  • You have access
    Effect of ethanol on the excitability of the inferior olive in decerebrate ferret.
    P Svensson, G Hesslow and R Winton
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 761-767;
  • You have access
    (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes.
    K Nunoya, Y Yokoi, K Kimura, T Kodama, M Funayama, K Inoue, K Nagashima, Y Funae, N Shimada, C Green and T Kamataki
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 768-774;
  • You have access
    Physiological release of striatal acetylcholine in vivo: modulation by D1 and D2 dopamine receptor subtypes.
    P DeBoer and E D Abercrombie
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 775-783;
  • You have access
    Opioid antagonists and antisera to endogenous opioids increase the nociceptive response to formalin: demonstration of an opioid kappa and delta inhibitory tone.
    M H Ossipov, C J Kovelowski, H Wheeler-Aceto, A Cowan, J C Hunter, J Lai, T P Malan and F Porreca
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 784-788;
  • You have access
    Depletion and refilling of acetylcholine- and caffeine-sensitive Ca++ stores in tracheal myocytes.
    X Liu and J M Farley
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 789-795;
  • You have access
    Acetylcholine-induced Ca++-dependent chloride current oscillations are mediated by inositol 1,4,5-trisphosphate in tracheal myocytes.
    X Liu and J M Farley
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 796-804;
  • You have access
    Identification of the human P450 enzymes involved in lansoprazole metabolism.
    R E Pearce, A D Rodrigues, J A Goldstein and A Parkinson
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 805-816;
  • You have access
    Lowered norepinephrine turnover as a sign of impaired ganglionic transmission after preganglionic lesioning by acetylcholinesterase antibodies.
    S McKinzie, G M Tyce and S Brimijoin
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 817-822;
  • You have access
    Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5-HT 1B receptors.
    S Consolo, S Arnaboldi, S Ramponi, L Nannini, H Ladinsky and G Baldi
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 823-830;
  • You have access
    Transport characteristics of differently charged cephalosporin antibiotics in oocytes expressing the cloned intestinal peptide transporter PepT1 and in human intestinal Caco-2 cells.
    U Wenzel, I Gebert, H Weintraut, W M Weber, W Clauss and H Daniel
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 831-839;
  • You have access
    In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    E M Kudlacz, S A Shatzer, R W Knippenberg, D E Logan, M Poirot, P L van Giersbergen and T P Burkholder
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 840-851;
  • You have access
    Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan.
    T H de Boer, F Nefkens, A van Helvoirt and A M van Delft
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 852-860;
  • You have access
    Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain.
    N Haddjeri, P Blier and C de Montigny
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 861-871;
  • You have access
    Dual effect of clonidine on mesenteric artery adrenoceptors: agonistic (alpha-2) and antagonistic (alpha-1).
    E G Silva, T Feres, L M Vianna, P Okuyama and T B Paiva
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 872-876;
  • You have access
    kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
    C C Taylor, D Wu, Y Soong, J S Yee and H H Szeto
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 877-884;
  • You have access
    Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors.
    J A Gibbons, A A Hancock, C R Vitt, S Knepper, S A Buckner, M E Brune, I Milicic, J F Kerwin, L S Richter, E W Taylor, K L Spear, R N Zuckermann, D C Spellmeyer, R A Braeckman and W H Moos
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 885-899;
  • You have access
    Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.
    S McLean, A Ganong, P A Seymour, D K Bryce, R T Crawford, J Morrone, L S Reynolds, A W Schmidt, S Zorn, J Watson, A Fossa, M DePasquale, T Rosen, A Nagahisa, M Tsuchiya and J Heym
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 900-908;
  • You have access
    Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
    M I Walton, W Gibson, G W Aherne, N Lawrence, T C Stephens, M N Smith and A L Jackman
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 909-916;
  • You have access
    Effect of tacrine on in vivo release of dopamine and its metabolites in the striatum of freely moving rats.
    U Warpman, X Zhang and A Nordberg
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 917-922;
  • You have access
    Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
    S T Crooke, M J Graham, J E Zuckerman, D Brooks, B S Conklin, L L Cummins, M J Greig, C J Guinosso, D Kornbrust, M Manoharan, H M Sasmor, T Schleich, K L Tivel and R H Griffey
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 923-937;
  • You have access
    Sodium 2,3-dimercaptopropane-1-sulfonate challenge test for mercury in humans. III. Urinary mercury after exposure to mercurous chloride.
    R M Maiorino, D Gonzalez-Ramirez, M Zuniga-Charles, Z Xu, K M Hurlbut, M M Aposhian, R C Dart, J S Woods, P Ostrosky-Wegman, M E Gonsebatt and H V Aposhian
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 938-944;
  • You have access
    Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice.
    T R Ozolins, D L Siksay and P G Wells
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 945-953;
  • You have access
    Neomycin selectively inhibits 5-hydroxytryptamine-induced contraction in the guinea pig trachea.
    D A Cox, S W Watts and M L Cohen
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 954-959;
  • You have access
    Discriminative stimulus effects on enadoline in pigeons.
    M R Brandt and C P France
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 960-967;
  • You have access
    Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
    J H Kehne, B M Baron, A A Carr, S F Chaney, J Elands, D J Feldman, R A Frank, P L van Giersbergen, T C McCloskey, M P Johnson, D R McCarty, M Poirot, Y Senyah, B W Siegel and C Widmaier
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 968-981;
  • You have access
    Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes.
    L C Wienkers, R C Steenwyk, P E Sanders and P G Pearson
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 982-990;
  • You have access
    Biotransformation of tirilazad in human: 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability.
    J C Fleishaker, P G Pearson, L C Wienkers, L K Pearson and G R Peters
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 991-998;
  • You have access
    Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    W Y Chan, N C Wo, L L Cheng and M Manning
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 999-1003;
  • You have access
    Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s.
    H Asai, S Imaoka, T Kuroki, T Monna and Y Funae
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1004-1009;
  • You have access
    Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
    M Nakajima, T Yamamoto, K Nunoya, T Yokoi, K Nagashima, K Inoue, Y Funae, N Shimada, T Kamataki and Y Kuroiwa
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1010-1015;
  • You have access
    Mapping the genes for haloperidol-induced catalepsy.
    S Kanes, K Dains, L Cipp, J Gatley, B Hitzemann, E Rasmussen, S Sanderson, M Silverman and R Hitzemann
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1016-1025;
  • You have access
    Down-regulation of metallothionein expression in human and murine hepatocellular tumors: association with the tumor-necrotizing and antineoplastic effects of cadmium in mice.
    M P Waalkes, B A Diwan, S Rehm, J M Ward, M Moussa, M G Cherian and R A Goyer
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1026-1033;
  • You have access
    Vasopressin mediates the pressor effects of endothelin in the subfornical organ of the rat.
    R Mosqueda-Garcia, R Fernandez-Violante, T Hamakubo and R Stainback
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1034-1042;
  • You have access
    Properties of Ca++ release induced by puff adder lectin, a novel lectin from the snake Bitis arietans, in sarcoplasmic reticulum.
    M Ohkura, Y Miyashita, T Nikai, J Suzuki, Y Komori, H Sugihara and Y Ohizumi
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1043-1048;
  • You have access
    Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
    K M Laughlin, S M Evans, W T Jenkins, M Tracy, C Y Chan, E M Lord and C J Koch
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1049-1057;
  • You have access
    Molecular mechanism for alkyl sulfide-modulated carbon tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and glutathione S-transferase expression.
    S G Kim, H C Chung and J Y Cho
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1058-1066;
  • You have access
    Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies.
    L R Walus, W M Pardridge, R M Starzyk and P M Friden
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1067-1075;
  • You have access
    Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity.
    G E Duncan, D J Knapp, K B Johnson and G R Breese
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1076-1089;
  • You have access
    Evaluation of immune parameters and lymphocyte production of prolactin-immunoreactive proteins after chronic administration of cocaine to pregnant rats.
    S A Masten, W J Millard, J L Karlix and K T Shiverick
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1090-1096;
  • You have access
    Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro.
    N Makkonen, M R Hirvonen, T Teräväinen, K Savolainen and J Mönkkönen
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1097-1102;
  • You have access
    The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats.
    S W Watts, M Baez and R C Webb
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1103-1113;
  • You have access
    Cocaine inhibits sympathetic neural activity by acting in the central nervous system and at the sympathetic ganglion.
    Y M Hernandez, V F Raczkowski, K L Dretchen and R A Gillis
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1114-1121;
  • You have access
    Involvement of the ventral tegmental area in locomotion elicited from the nucleus accumbens or ventral pallidum.
    K Johnson, L Churchill, M A Klitenick, M S Hooks and P W Kalivas
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1122-1131;
  • You have access
    Characterization of the cloned HEL cell thromboxane A2 receptor: evidence that the affinity state can be altered by G alpha 13 and G alpha q.
    C J Allan, K Higashiura, M Martin, T A Morinelli, D T Kurtz, O Geoffroy, G P Meier, T W Gettys and P V Halushka
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1132-1139;
  • You have access
    Glial cell line-derived neurotrophic factor sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to nerve growth factor and brain-derived neurotrophic factor.
    L R Williams, G Inouye, V Cummins and M A Pelleymounter
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1140-1151;
  • You have access
    Procollagen gene expression is down-regulated by taurine and niacin at the transcriptional level in the bleomycin hamster model of lung fibrosis.
    G Gurujeyalakshmi, S N Iyer, M A Hollinger and S N Giri
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1152-1157;
  • You have access
    Determinants of the response of neuroblastoma cells to DNA damage: the roles of pre-treatment cell morphology and chemical nature of the damage.
    T L Hartsell, L M Hinman, P R Hamann and N F Schor
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1158-1166;
  • You have access
    Quantitative assessment of blood-brain barrier damage during microdialysis.
    M E Morgan, D Singhal and B D Anderson
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1167-1176;
  • You have access
    Evidence for selective involvement of dopamine D1 receptors of the ventral tegmental area in the behavioral sensitization induced by intra-ventral tegmental area injections of D-amphetamine.
    Y Bjijou, L Stinus, M Le Moal and M Cador
    Journal of Pharmacology and Experimental Therapeutics May 1996, 277 (2) 1177-1187;
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 277, Issue 2
1 May 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
  • Functional Selectivity and Classical Concepts of Quantitative Pharmacology
  • Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
  • The Prediction of Human Pharmacokinetic Parameters from Preclinical and In Vitro Metabolism Data
  • A METHOD FOR DETERMINING LOSS OF PAIN SENSATION
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics